A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment
Open Access
- 14 October 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 22 (10), 1495-1504
- https://doi.org/10.1093/neuonc/noaa101
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a highly lethal malignancy that occurs predominantly in children. DIPG is inoperable and post-diagnosis survival is less than 1 year, as conventional chemotherapy is ineffective. The intact blood–brain barrier (BBB) blocks drugs from entering the brain. Convection-enhanced delivery (CED) is a direct infusion technique delivering drugs to the brain, but it suffers from rapid drug clearance. Our goal is to overcome the delivery barrier via CED and maintain a therapeutic concentration at the glioma site with a payload-adjustable peptide nanofiber precursor (NFP) that displays a prolonged retention property as a drug carrier. The post-CED retention of 89Zr-NFP was determined in real time using PET/CT imaging. Emtansine (DM1), a microtubule inhibitor, was conjugated to NFP. The cytotoxicity of the resulting DM1-NFP was tested against patient-derived DIPG cell lines. The therapeutic efficacy was evaluated in animals bearing orthotopic DIPG, according to glioma growth (measured using bioluminescence imaging) and the long-term survival. DM1-NFP demonstrated potency against multiple glioma cell lines. The half-maximal inhibitory concentration values were in the nanomolar range. NFP remained at the infusion site (pons) for weeks, with a clearance half-life of 60 days. DM1-NFP inhibited glioma progression in animals, and offered a survival benefit (median survival of 62 days) compared with the untreated controls (28 days) and DM1-treated animal group (26 days). CED, in combination with DM1-NFP, complementarily functions to bypass the BBB, prolong drug retention at the fusion site, and maintain an effective therapeutic effect against DIPG to improve treatment outcome.Keywords
Funding Information
- National Cancer Institute (R01 CA222802)
- U.S. Department of Defense (CA160373)
This publication has 28 references indexed in Scilit:
- Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutationsNature Genetics, 2014
- A short circulating peptide nanofiber as a carrier for tumoral deliveryNanomedicine: Nanotechnology, Biology and Medicine, 2013
- In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine GliomaPLOS ONE, 2013
- Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfallsJournal of Neuro-Oncology, 2011
- Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticlesInternational Journal of Nanomedicine, 2011
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid ConjugatesBioconjugate Chemistry, 2009
- ANATOMIC COMPRESSION CAUSED BY HIGH-VOLUME CONVECTION-ENHANCED DELIVERY TO THE BRAINNeurosurgery, 2009
- Protease-Sensitive Fluorescent NanofibersBioconjugate Chemistry, 2007
- Diffuse brainstem glioma in children: critical review of clinical trialsThe Lancet Oncology, 2006
- Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and EfficacyCancer Research, 2006